Pharmaids Pharmaceuticals Debt & Borrowing: ₹0.55 Cr

Pharmaids Pharmaceuticals Q2 FY27 Results: Net Loss of ₹1.8 Cr, Loss Narrows

Pharmaids Pharmaceuticals Ltd reported revenue from operations of ₹4.3 Cr (-50.0% YoY) and a net loss of ₹1.8 Cr for Q2 FY27.

Key figure

Net loss ₹1.8 Cr

Pharmaids Pharmaceuticals Board Meeting Date

Pharmaids Pharmaceuticals Ltd intimated BSE of a board meeting on 11 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The notice contains no figures, and the trading window stays closed from 1 October 2026.

Pharmaids Pharmaceuticals Other Announcement

Pharmaids Pharmaceuticals Limited filed its quarterly Regulation 74(5) compliance certificate from its Registrar and Share Transfer Agent confirming the dematerialization of shares.

Pharmaids Pharmaceuticals Legal & Regulatory

Pharmaids Pharmaceuticals filed legal complaints against Anugraha Chemicals for dishonoured cheques totalling ₹2.63 Crore in outstanding dues from a disinvestment agreement.

Value

₹2.63 Cr

Pharmaids Pharmaceuticals Annual General Meeting

Pharmaids Pharmaceuticals held its 37th AGM via video conference on 11 Sept 2026. Four resolutions including adoption of FY26 financials and related-party-transaction approvals were tabled.

Pharmaids Pharmaceuticals Promoter Buying (Off-Market)

KMP Prasanna Subramanya Bhat acquired 17,291 shares of Pharmaids Pharmaceuticals Ltd via a gift from an immediate relative. This off-market transfer is an insider disclosure.

Promoter stake change

+0.04%

HDFC Life Insurance Company Debt & Borrowing

HDFC Life intimated a CRC meeting on November 16, 2026, to approve commercial terms for up to ₹500 Crore of unsecured subordinated NCDs. The filing only schedules the meeting; no terms are yet approved.

Repco Home Finance Debt & Borrowing

Repco Home Finance submitted a revised Security Cover and Covenant Compliance Certificate as of 30 September 2026, extending compliance coverage to all Debenture Trust Deed covenants. The revision follows the earlier certificate and only changes the covenant scope and UDIN.

Triveni Turbine Debt & Borrowing: ₹56.21 Cr

Triveni Turbine enhanced its corporate guarantee for subsidiary TTAPL by USD 6 million. Guarantee amount is Rs.56.21 Crore, lifting the facility limit to USD 15 million.

Value

₹56.21 Cr

TSF Investments Debt & Borrowing

TSF Investments' board approved up to ₹1,500 Crore in debt instruments of group companies. The material related-party deal needs shareholder approval via postal ballot.

Motilal Oswal Financial Services Debt & Borrowing: ₹150 Cr

Motilal Oswal Financial Services certified timely payment of the Rs.150 Crore maturity on commercial paper ISIN INE338I14NE7, due 11 November 2026. This confirms fulfilment of a debt obligation.

Value

₹150.0 Cr

Glottis Debt & Borrowing: ₹60 Cr

Glottis's board approved up to ₹60 Crore of interest-free unsecured loans from two Managing Directors. The related-party loans fund working capital and are not at arm's length.

Value

₹60.00 Cr

Execution

Up to 5 years from each tranche disbursement